Introduction
Pulmonary arterial hypertension (PAH) is a severe and frequently fatal disease that is caused by narrowing of the distal pulmonary vascular circulation leading to elevated pulmonary arterial pressure, right heart failure and death. Although pulmonary vascular tone is increased, most of the increase in pulmonary vascular resistance is caused by remodelling of the distal pulmonary vasculature. This remodelling includes endothelial dysfunction, smooth muscle cell hyperplasia and hypertrophy, as well as adventitial fibroblast proliferation, myofibroblast differentiation, and extracellular matrix deposition. 1, 2 The mechanisms responsible for these myriad changes are not well understood, but include endothelial apoptosis and the emergence of hyper-proliferative, apoptosis resistant endothelial cells (ECs) that display a metabolic switch to predominantly glycolytic pathways. 3 Atypical abundances of functionally distinct ECs have been extensively reported to precede muscularization of distal life to adulthood, these haemangioblasts are readily identifiable in the BM in a small subpopulation of CD34þ haematopoietic stem cells (HSCs) that also demonstrate selective expression of CD133. Recent studies have shown that CD34þ CD133þ progenitors are increased in the plasma, BM and lungs of PAH patients compared with controls and that plasma levels of these cells correlate with severity of PAH. Farha et al. recently reported that CD34þ 133þ cells from PAH patients have greater proliferative capacity than circulating progenitors of healthy controls. They also showed that non-affected family members of patients with familial PAH displayed elevated circulating concentrations of CD34þ CD133þ cells, which were comparable with their affected relatives with PAH. Non-affected family members also had significant increase in marrow fibrosis compared with healthy unrelated controls.
The investigators hypothesized that a subclinical myeloproliferative process is intrinsic to PAH, and that these myeloid abnormalities promote the pathologic vascular remodelling in the lung. 7 This hypothesis is further supported in a follow-up study in which mice transplanted with BM-derived CD133þ progenitor cells from patients with PAH developed pulmonary hypertension (PH). 8 Furthermore, marked infiltration of c-kitþ haematopoietic progenitor cells, especially in the perivascular compartment of remodelled arteries of idiopathic PAH patients has been reported 9 and therapeutic targeting of c-kitþ cells prevents hypoxia-induced PAH in mice. 10 In adult mammals, including humans, blood cells arise from multilineage HSCs in the BM and thymus. 11 However, during embryonic development, haematopoiesis begins in the yolk sac from an endothelium with haemogenic properties, known as the haemogenic endothelium, first identified in the 1900s based on microscopic observations of developing embryos. [12] [13] [14] Later, Murray et al. 15 referred to the same cells as 'haemangioblasts' suggesting both endothelial and blood cells develop from them. Studies with murine embryos confirm findings in the haemangioblasts as a common precursor for endothelial and haematopoietic cells. 16 It is now believed that HSCs responsible for the generation of all blood cell types can arise from the haemogenic endothelium, 17,18 a hypothesis that is supported by recent time-lapse imaging experiments that visualized the transition of endothelium into blood in real-time, both in vitro 19 and in/ex vivo. [20] [21] [22] The process of ECs taking on a haematopoietic fate has been termed endothelial-to-haematopoietic transition (EHT), and is regulated by a specific set of transcription factors, such as Fli1, Scl/Tal1, Lmo2, Runx1, GATA1, GATA2. [23] [24] [25] [26] Whether haemogenic ECs exist in adulthood and generate HSCs is currently unknown. Embryonic lineage-tracing studies, which label haemogenic ECs before definitive haematopoiesis and follow their progenies through adulthood, demonstrate that, although embryonic HSCs remain functional in adulthood, they do not account for all haematopoietic cells generated postnatally. 18 In this study, we hypothesize that BM-derived EPCs acquire a haematopoietic phenotype via EHT which then lead to the vascular pathology in experimental PH. We demonstrate that during PH development in mice, EPCs mobilize from BM into the circulation, and these EPCs have haematopoietic properties and can be found in the remodelled pulmonary vasculature. Inhibition of EHT by blocking Runx1, one of the key transcription factors responsible for EHT, prevented disease progression in both Sugen/hypoxia (Su/Hx)-and monocrotaline (MCT)-induced PH mouse models. Furthermore, we found high levels of Runx1 expression in circulating CD34þ CD133þ EPCs isolated from peripheral blood of PH patients, supporting the clinical relevance of our proposed mechanism of EHT.
Methods

Mouse strains and procedures
Mice with endothelial specific expression of Cre recombinase (VE-cadherin-cre 27 ), Rosa26-ZsGreen reporter mice, CD45.1 mice and C57BL/ 6 J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were 6-to 10-weeks old when used for experiments. Genotyping was carried out with primers and conditions as recommended by The Jackson Laboratory. For euthanasia, the mice were sacrificed via CO 2 asphyxia followed by cervical dislocation. All animal experiments were approved by the Rhode Island Hospital (RIH) IACUC, and were performed conform the NIH guidelines (Guide for the care and use of laboratory animals).
Su/Hx-induced and MCT-induced PH mouse models
Although debate over validity of different PH mouse models is still ongoing, we chose Su/Hx-induced and MCT-induced PH mouse models for this study. [28] [29] [30] The Su/Hx-PH protocol consisted of 3 weekly s.c.
injections of the Sugen VEGF receptor-2 inhibitor SU5416 (Tocris) at 20 mg/kg in 100 ll DMSO or vehicle alone. 31 During the 3-week SU5416 treatment, mice were exposed to hypoxia (8.5% O 2 ) or normoxia (Nx) for 3 weeks. For the MCT-induced PH mouse model, cohorts of mice received weekly subcutaneous injections of MCT (60 mg/kg, Sigma) resuspended in 100 ll of saline or 100 ll of saline only (vehicle) for 4 weeks. Mice were sacrificed 1 week after the last MCT injection. Development of PH was determined by measurement of right ventricular systolic pressure (RVSP), right ventricular (RV) hypertrophy (i.e. Fulton's index) and pulmonary vascular remodelling (i.e. vessel muscularization and wall thickness index). To measure RVSP, mice were anaesthetized via intra-peritoneal injection with ketamine (100 mg/kg) and xylazine (10 mg/ kg). RVSP was measured through a trans-thoracic route with a Millar catheter transducer PVR-1030 (ADInstruments Inc., Colorado Springs, CO) and data were collected and analysed using the LabChart software v8. 1.3 
Immunofluorescence confocal imaging
Runx1 inhibition in vivo
One week after Su/Hx-PH induction in C57BL/6 J mice or in the VEcadherin-cre; ZsGreen mice, specific CBFb-Runx1 inhibitor Ro5-3335 32 (EMD Millipore, Billerica, MA) was administered s.c. every other day at 50 mg/kg. Alleviation of PH was evaluated in inhibitor treated mice compared with vehicle injected control mice. The numbers of ZsGreenþ CD45þ cells in the peripheral blood of the VE-cadherin-cre; ZsGreen mice were analysed to determine whether Runx1 inhibition prevents potential EHT and PH progression. The numbers of ZsGreenþ c-kitþ CD45-EPCs in the BM of the double transgenic mice were also measured by using flow cytometry to determine whether Ro5-3335 intervention inhibits their egression.
Isolation of circulating CD34þ CD133þ EPCs from PH patients
Peripheral blood samples (12 ml each) were collected from healthy controls and from patients with PH who were undergoing right heart catheterization at the RIH Pulmonary Hypertension Center as part of their routine clinical evaluation. PH and PAH were defined according to consensus criteria using standard haemodynamic definitions. [33] [34] 421, CD34-Alexa Fluor 488, CD133-APC and VEGFR2-PE. DAPI was used to exclude dead cells. Human CD34þ CD133þ EPCs were collected by using a BD Influx cell sorter (BD Biosciences).
Quantitative RT-PCR of Runx1 expression
Total RNA was purified from patient and healthy control EPCs by using RNeasy Mini kit (Qiagen). First-strand cDNA was synthesized by using 
Statistical analysis
Data are shown as the mean values ± S.E.M. The significance of difference was calculated with unpaired two-tailed Student's t-test or oneway ANOVA when comparing more than two groups by using GraphPad Prism version 6.03 (GraphPad Software, Inc., La Jolla, CA). P values < 0.05 were considered to be statistically significant.
Results
Assessment of the Su/Hx-induced PH mouse model
We used wild-type C57BL/6 J mice to establish the Su/Hx-PH mouse model by injecting a VEGFR2 inhibitor SU5416 once weekly during 3 weeks of hypoxia (8.5% O 2 ) ( Figure 1A Figure 1B) . Su/Hx treated mice also had RV hypertrophy as indicated by a significant increase in the Fulton's index (RV/LV þ S) compared with Nx and Su/ Nx mice ( Figure 1C) . Upon immunostaining of a-SMA in the lung sections, significantly increased muscularization of distal pulmonary arteriole (<50 lm in diameter) vessel wall was also determined in the Su/Hxtreated mice compared with Nx and Su/Nx mice ( Figure 1D -F, see Supplementary material online, Figure S1A and B). In addition, morphometric analysis of pulmonary arterioles suggested that Su/Hx treated mice had significant pulmonary vascular remodelling compared with Nx controls (see Supplementary material online, Figure S1C -E).
Thus, Su/Hx-induced PH model produced appreciable PH pathology in mice.
Lineage tracing of cells with endothelial origin during PH development
In order to track potential in vivo transformation of ECs during PH induction, we generated VE-cadherin-cre; ZsGreen double transgenic mice, in which all ECs and EPCs were permanently labelled with the fluorescence protein ZsGreen. As shown in the frozen lung sections of the double transgenic mice, both large vessels and small capillaries were labelled green while epithelial bronchiolar airways, as internal negative controls, were not labelled green ( Figure 2A , see Supplementary material online, Figure S2A and B). In addition to the lung, genetic labelling of vascular ECs in the heart and femur was also apparent when compared with respective tissue in the parental Rosa26-ZsGreen mice (see Supplementary material online, Figure S2C -F). Immunostaining of von Willebrand factor (vWF) was also performed in lung sections of the VE-cadherin-cre; ZsGreen double transgenic mice, which exhibited similar staining pattern as previously published. 35 Confocal fluorescence microscopy image of pulmonary arterioles showed that the vessel lumen lining ECs were costained with ZsGreen and vWF (see Supplementary material online, Figure S3 ). These VE-cadherin-cre; ZsGreen double transgenic mice were then subjected to Su/Hx treatment to induce PH, and 50 ll of peripheral blood samples were taken weekly ( Figure 2B) . It is worth noting that the VE-cadherin promoter is active in a small fraction of the haemangioblasts during embryonic development. 27 Our analysis suggests that approximately 20-30% of peripheral blood cells of the double transgenic mice are already labelled by ZsGreen (Nx W0 in Figure 2C and D). These results suggest that cells of endothelial origin have transformed into haematopoietic cells with myeloid propensity during PH development.
Egression of EPCs from the BM and their detection in the lung of PH mice
In comparison with the parental Rosa26-ZsGreen mice ( Figure 3A and see Supplementary material online, Figure S2E ), in vivo labelling of BM cells with endothelial origin in the double transgenic mice is shown in Figure 3B and see Supplementary material online, Figure S2F . The percentage of ZsGreenþ CD45þ cells in the BM remained constant during the 3 weeks of Su/Hx treatment, which were comparable to that of Nx mice ( Figure 3C and D) . Next, based on the postulation that ZsGreenþ, i.e. activation of VE-cadherin promoter, represents endothelial origin, c-kitþ labels progenitor cells and CD45-indicates non-haematopoietic, 6 ,36,37 we used the combination ZsGreenþ c-kitþ CD45-to identify putative EPCs in the mouse BM. Intriguingly, the percentage of ZsGreenþ c-kitþ CD45-EPCs decreased dramatically in a time-dependent manner following Su/Hx treatment ( Figure  3E) . Furthermore, by using immunofluorescence staining and confocal microscopy we could identify a significant number of both ZsGreenþ c-kitþ cells and ZsGreen-c-kitþ cells (indicated by arrows and arrow heads, respectively, in Figure 4A and see Supplementary material online, Figure S4A ) in the Su/Hx mouse lungs, whereas no c-kitþ cells were detected in the Nx mouse lungs ( Figure 4B and see Supplementary material online, Figure S4B ). 
BM cells depleted of EPCs are unable to transfer PH pathology to recipient mice
A recent study suggests that BM cells may play a key role in PH pathogenesis and that the transplanted BM cells from Bmpr2 mutant mice were able to drive the lung phenotype in a myeloablative transplant model. 38 We sought to test if BM cells from Su/Hx mice were able to cause PH pathology in transplant recipient mice. Total BM cells from Su/ Hx treated mice were transplanted into lethally irradiated mice. RV hypertrophy of the recipient mice was assessed 4 weeks post-transplantation. The results showed that BM cells depleted of EPCs were unable to transfer PH pathology to recipient mice (see Supplementary material online, Figure S5 ). 
The putative EPCs from BM are haemogenic with myeloid propensity
By using a BD Influx cell sorter, we isolated from mouse BM the ZsGreenþ c-kitþ CD45-EPCs for haematopoietic gene expression analysis ( Figure 5A) . The results were then compared with gene expression profile of the BM-derived LSK population which is enriched with HSCs 39 ( Figure 5B) . We found that all critical transcription factors for haematopoiesis were expressed by the ZsGreenþ c-kitþ CD45-cells, including Cbfb, GATA1, GATA2, Lmo2, Runx1, and Scl/Tal1 40 ( Figure   5C ). In addition to the transcription factors, key regulators and markers of haematopoiesis such as Nos2 and Vav1 were also expressed in the ZsGreenþ EPCs ( Figure 5C and see Supplementary material online, Table S1 ). Notably, several genes involved in myeloid-erythroid lineage differentiation (Ahsp, GATA1 and Trim10) were expressed at a higher level in the ZsGreenþ EPCs than in the LSK cells, whereas most other genes were expressed on a comparable level between the two cells ( Figure 5D ). Next, we transplanted the ZsGreenþ c-kitþ CD45-EPCs into lethally irradiated mice. In syngeneic BM transplantation, C57BL/6 J mice with CD45.1 marker are often used as recipients and injected with haematopoietic stem and progenitor cells from congenic mice with CD45.2 marker. In this context, the donor or recipient cells can be easily identified by their allotypes of the leukocyte common antigen CD45. Donor-derived CD45.2þ haematopoietic cells were detected in the CD45.1 recipient mice 8 and 16 weeks post-transplantation ( Figure 5E ). Since the ratio of donor cell to CD45.1 radio-protective cell was 1: 100 (3 Â 10 3 to 3 Â 10 5 ), the maximal chimerism of donor-derived CD45.2 blood cells in the recipient would be 1%. Combined, these results strongly suggest that endothelium-derived progenitor cells from BM have the capability to undergo myeloid skewed haematopoiesis in vivo.
Runx1 inhibition blocks EHT in vivo and prevents egression of the EPCs from BM
Although transcription factors Fli1, Scl/Tal1, and Lmo2 are critical for earlier embryonic processes involved in endothelium specification from mesoderm, GATA2 is required for HSC generation and survival. 16, 26, 41 One transcription factor that has been a particularly useful marker of this developmental event in multiple species is Runx1, which is required for the EHT but not thereafter. 25, 42 A recent high-throughput screening study revealed that a chemical compound Ro5-3335 was able to interrupt Runx1 binding to its heterodimeric partner CBF b, suppress Runx1-dependent haematopoiesis and inhibit leukemia in a mouse model. 32 We tested whether Ro5-3335 (50 mg/kg) or vehicle control could block Runx1-dependent EHT in the VE-cadherin-cre; ZsGreen double transgenic mice in Su/Hx-PH model ( Figure 6A) . One week into Su/Hx treatment, the percentage of ZsGreenþ CD45þ cells in the peripheral blood increased significantly ( Figure 6B and C) . However, when the mice were treated with Ro5-3335 every other day, the accumulation of the ZsGreenþ CD45þ cells in the peripheral blood diminished after 2 as well as 3 weeks of Su/Hx treatment ( Figure 6B and C) . Furthermore, the administration of Ro5-3335 significantly prevented egression of the ZsGreenþ c-kitþ CD45-EPCs from BM. After 3 weeks of Su/Hx treatment, the percentage of the ZsGreenþ c-kitþ CD45-EPCs in the BM of Su/Hx/Ro5 mice was significantly higher than that in Su/Hx mice, and had no difference compared with Nx mice ( Figure 6D and E).
Runx1 inhibition prevents Su/Hxinduced PH in mice
To determine if Ro5-3335 inhibition of EHT resulted in amelioration of pulmonary hypertensive changes, we examined whether targeting Runx1 in vivo could prevent PH progression in mice ( Figure 7A) . After 3 weeks of Su/Hx treatment, RVSP and RV hypertrophy were significantly lower in mice treated with Ro5-3335 (Su/Hx/Ro5) than in mice without Ro5-3335 treatment (Su/Hx), and had no difference compared with Nx mice ( Figure 7B and C) . Immunostaining of a-SMA showed augmented muscularization in the distal pulmonary arteriole vessel walls of Su/Hx mice compared with Nx control mice and Ro5-3335 treated mice ( Figure 7D -G, see Supplementary material online, Figure S6A -C).
Morphometric analysis of pulmonary vessels also indicted that treatment with Ro5-3335 prevented pulmonary vascular remodelling. Pulmonary arteriole wall thickness index increased significantly in Su/Hx mice compared with Nx control mice and Ro5-3335 treated mice (see Supplementary material online, Figure S6D -G). These results suggest that specific Runx1 inhibition in vivo can prevent Su/Hx-induced PH in mice.
Runx1 inhibition alleviates MCTinduced PH in mice
In order to test if EHT may also contribute to the development of PH in other animal models of the disease, we applied Runx1 inhibitor Ro5-3335 in the MCT-induced PH mouse model (see Supplementary material online, Figure S7A ). MCT treated mice developed significantly elevated RVSP, RV hypertrophy and vascular remodelling. Although injection of the Runx1 inhibitor Ro5-3335 did not reverse RVSP (see Supplementary material online, Figure S7B ), the treatment reduced RV hypertrophy (see Supplementary material online, Figure S7C ) as well as distal pulmonary vessel muscularization (see Supplementary material online, Figure S7D -G) in MCTþ Ro5-3335 group. These results suggest that specific Runx1 inhibition in vivo can also alleviate MCT-induced PH in mice.
High level expression of Runx1 in circulating EPCs isolated from PH patients
To further establish clinical relevance of our studies, we isolated CD34þ CD133þ EPCs from peripheral blood of patients diagnosed with PH.
Patient characteristics, PH-subtype, haemodynamics (either at baseline or during follow-up catheterization) and concurrent PAH treatments at the time of study enrollment and blood draw are included in see Supplementary material online, Table S2 . Based on our flow cytometry analysis, these EPCs constitute about 0.01-0.05% of total peripheral blood cells and they were collected by using a BD Influx cell sorter. Given the small sample volume (12 ml peripheral blood from each patient), no CD34þ CD133þ VEGFR2þ cells were detected, as the (see Supplementary material online, Figure S8A-E) . Next, we performed quantitative RT-PCR to show that Runx1, the critical haematopoietic transcription factor required for EHT, was highly expressed in the circulating EPCs of PH patients (see Supplementary material online, Figure  S8F ). These data demonstrate that Runx1 expression is increased in EPCs from patients with PH and support our hypothesis that EHT may play a role in human disease.
Discussion
Current therapies for PAH produce modest improvements in pulmonary vascular resistance and functional capacity and are effective at delaying the time to clinical worsening, but none of the interventions are etiology-based. Further advances in treatments will require therapies that inhibit and reverse the underlying causes of the disease. Here, we sought to determine if inflammatory cells that have been implicated in induction of pulmonary vascular remodelling in PAH derive in part from EHT and if blocking EHT could prevent disease progression.
Although no currently available model recapitulates all the features of human PAH, we used the combination of VEGF receptor-2 antagonist SU5416 and hypoxia to induce PH in mice. This model causes a more profound and sustained PH phenotype than with hypoxia alone, and allows the use of genetically modified mice to delineate potential pathogenic mechanisms. In consideration of our hypothesis of EHT, the use of VEGFR-2 blocker is attractive because it could facilitate the generation of many hyper-proliferative and apoptosis-resistant ECs and EPCs that would serve as the source of EHT. Ciuclan et al. observed occluded pulmonary arterioles in mice immediately after 3 weeks of Su/Hx but did not quantify these lesions. 29 However, no angio-obliterative lesions were found in our Su/Hx-mice, which is in agreement with recent reports by other investigators. 28, 44 In this study, 3 weeks of treatment with Su/Hx resulted in the development of appreciable PH pathology in mice as evidenced by a significant increase of RVSP as well as a >50% increase in pulmonary vascular muscularization and RV free wall mass. During the development of PH in Su/Hx treated mice, we found a significant increase in circulating haematopoietic cells of endothelial origin as evidenced by the percentage increase in ZsGreenþ CD45þ cells in peripheral blood. At the same time we found no change in the percentage of the ZsGreenþ CD45þ haematopoietic cells in the BM, but did observe a marked reduction in the amount of ZsGreenþ c-kitþ CD45-EPCs in the BM. The appearance of these cells in distal pulmonary vessels suggests a mobilization of the EPCs from BM into the lung. Despite the exponential rise in EPC research, the phenotypic classification of EPCs remains elusive. 37 In this study, the ZsGreenþ c-kitþ CD45-cells FACS sorted from BM expressed in addition to VE-cadherin (CD144) and c-kit (CD117) also the EC markers CD34 and PECAM (CD31) but not haematopoietic marker CD45 or monocyte/macrophage marker CD14 as indicated by the gene array analysis. As such, these cells definitely have endothelial markers but lack markers of blood cells. Concomitantly, they express a number of key haematopoietic transcription factors and are capable of reconstituting lethally irradiated recipient mice. The fact that these ZsGreenþ c-kitþ CD45-CD14-cells are haemogenic endothelial in nature and are capable of differentiating into haematopoietic cell lineages strongly suggests that the de novo production of ZsGreenþ CD45þ haematopoietic cells in PH mice is a bona fide EHT. Next, we found that BM cells from Su/Hx mice depleted of EPCs were unable to cause PH in transplant recipient mice, which supports the notion that BM-derived EPCs play a critical role in the pathogenesis of Su/Hx-PH in mice. In a separate study, we showed that BM-derived EPCs from MCT-PH mice could induce PH in healthy mice, but BM cells depleted of EPCs could not. 45 Further investigation in which transplantation of peripheral blood-derived ZsGreenþ CD45þ cells from Su/Hx-PH mice is warranted to directly demonstrate if these cells can cause PH in transplant recipients.
We further showed that inhibition of EHT by administration of a specific Runx1 inhibitor Ro5-3335 prevented the rise in ZsGreenþ CD45þ haematopoietic cells in peripheral blood and the fall in ZsGreenþ ckitþ CD45-EPCs in BM during Su/Hx-induced PH. Despite Su/Hx treatment, Runx1 inhibition blocked the egress of endothelial-derived EPCs from BM, prevented the increase of RVSP, pulmonary vascular remodelling as well as the development of RV hypertrophy. The molecular mechanisms with which Runx1 inhibition prevents the egression of EPCs from the BM remains unclear, but it is possible that downstream signals in the EPCs required for their mobilization (e.g. expression of cytokine receptors) become absent or reduced. Further experiments are needed to compare gene expression profiles in pulmonary versus BM-derived ZsGreenþ c-kitþ CD45-EPCs. In addition, we also used another mouse model of PH to demonstrate efficacy of the Runx1 inhibitor Ro5-3335. The MCT-induced PH model in mice has been well-established and was used in our previous studies. 30, 46 Runx1 inhibition in this model of PH prevented RV hypertrophy and pulmonary vascular remodelling but not the increase of RVSP. We speculate that the timing and duration of the Runx1 inhibitor intervention may need further optimization to obtain best outcome. It is also possible that in addition to EHT other disease mechanisms are also important in the MCT-induced PH mouse model. Combined, these findings indicate that EHT-derived haematopoietic cells play a critical role in the development of disease in experimental PH. The VE-cadherin-cre; ZsGreen double transgenic mice showed inherently a 20-30% penetration in the haematopoietic lineage. This means that the VE-cadherin promoter was activated in a number of blood cells derived from haemogenic ECs during embryonic development, making it difficult to distinguish haematopoietic cells derived from EHT associated with experimental PH. We reason that the percentage increase in ZsGreenþ CD45þ cells is the result of de novo haematopoietic differentiation via EHT rather than proliferation of existing ZsGreenþ CD45þ cells, since ZsGreen-CD45þ cells would have proliferated in the same rate as well. Nevertheless, we cannot exclude the possibility that ZsGreenþ CD45þ and ZsGreen-CD45þ cells may behave differently. To overcome this limitation and to enhance endothelial specificity in lineage tracing, further experiments using inducible VE-cadherincreERT2; ZsGreen mice in Su/Hx-PH model are ongoing in our laboratory.
Inflammation has recently been implicated as an integral factor during HSC emergence from haemogenic endothelium. 47 In the lung, injury to the endothelium by environmental factors is thought to be one of the precipitating events in PAH. At the onset of PAH, neutrophils or other inflammatory signals may traverse into BM to invoke haemogenic EPCs and initiate EHT. Previous studies have suggested that HIF-1a-induced factors such as erythropoietin, hepatocyte growth factor, SCF or VEGF are released by pulmonary vascular ECs to stimulate mobilization of BMderived EPCs. 48 These stimuli may activate EHT which in turn produces pro-angiogenic myeloid cells that home to the lung, causing perivascular inflammation and remodelling. At the molecular level, Lancrin et al. demonstrated that the transcription factor Scl/Tal1 is indispensable for the establishment of the haemogenic endothelium population, 49 whereas the core binding factor Runx1 is critical for generation of definitive haematopoietic cells from haemogenic endothelium. 25 The regulatory regions of haematopoietic genes are known to be bound by Runx1, as well as a transcription factor complex composed of Scl/Tal1, Lmo2, GATA1, and GATA2, all of which have been implicated in EHT. 16, 40, 50 All of these transcription factors were found to be highly expressed by the ZsGreenþ c-kitþ CD45-EPCs isolated from mouse BM. The expression of c-kit is another distinguishing feature of haemogenic relative to non-haemogenic ECs. 36 Failure to resolve inflammation and altered immune processes are thought to underlie the development of PAH. 51 Lung inflammation precedes vascular remodelling in experimental PH suggesting that altered immunity is a cause rather than a consequence of vascular disease. 52 Increasing data indicate that inflammatory and immune mechanisms contribute to pulmonary vascular disease and this may be reflected in mobilization of cells from the BM. Thus, cells such as lymphocytes, monocytes, macrophages, and dendritic cells accumulate in pulmonary vascular lesions and raised levels of inflammatory mediators occur in the lungs and circulation of PAH patients. 8, 38, 53 Recent studies suggested that pulmonary tertiary lymphoid tissues could be directing local immune phenomena. 54, 55 It is plausible that EHT may contribute to the ectopic lymphoid follicles in the lung. Reduced BMPR2 expression, a common feature of PAH, induces GM-CSF translation 56 which may potentially exacerbate myeloid skewed EHT. Based on our current findings, reducing the number of EPCs in the circulation and blocking EHT of these cells could provide a potential strategy to alleviate PAH. Since differentiation of blood cells from the haemogenic endothelium is critically dependent on Runx1 expression, and Runx1 is likely to become dispensable beyond the haemogenic endothelium stage, this combination would make Runx1 a desirable target for treating pulmonary vascular disease in patients without affecting other physiological processes. Indeed, we could show that Runx1 is highly expressed in the circulating EPCs of PH patients, which provides important evidence that our proposed mechanism of EHT in animal models of PH may also be valid in human disease. This signal was significant despite the inclusion of several patients with PH from left heart disease (combined pre-and post-capillary PH and pure pulmonary venous hypertension); evidence of EHT may be even more apparent in a population of untreated 'pure' PAH patients. Isolation of EPCs from a larger cohort of only PAH patients (four of the patients in the current sample) should be performed to confirm our findings. Further clinically relevant experiments are warranted to test the Runx1 inhibitor in Su/Hx/Nxmodel in rats that develop severe PH accompanied by occlusive pulmonary arterial neointimal and plexiform lesions. 57 In summary, data from this study suggest that during the development of PH, BM-derived EPCs mobilize into the circulation and eventually the pulmonary vasculature where they play a critical role through the process of a myeloid skewed EHT. Blocking this process by specific inhibition of Runx1, one of the key transcription factors responsible for EHT, not only prevents the mobilization of EPCs but prevents disease progression in mice with Su/Hx-and MCT-induced PH. Finally, EPCs isolated from the blood of patients with PH have increased expression of Runx1. Together, these findings suggest that EHT plays an important role in the pathogenesis of PAH and that the haematopoietic transcription factor Runx1 may be a novel therapeutic target to treat PAH.
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